The New England journal of medicine, 2021-09, Vol.385 (14), p.1280-1291
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
- Ist Teil von
- The New England journal of medicine, 2021-09, Vol.385 (14), p.1280-1291
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In a phase 3 trial, patients with moderately to severely active ulcerative colitis were randomly assigned to receive placebo or ozanimod, a selective sphingosine-1-phosphate receptor modulator. Clinical remission was significantly greater with ozanimod during the induction and maintenance periods. The incidence of infection was higher with ozanimod than with placebo during maintenance.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2033617Titel-ID: cdi_proquest_miscellaneous_2578152044
- Format
- –
- Schlagworte
- Adult, Bradycardia - chemically induced, Cardiac arrhythmia, Chicken pox, Clinical trials, Colitis, Ulcerative - drug therapy, Double-Blind Method, Edema, Endoscopy, Female, Gastroenterology, Humans, Hypertension - chemically induced, Indans - adverse effects, Indans - therapeutic use, Induction Chemotherapy, Inflammatory Bowel Disease, Inflammatory bowel diseases, Intention to Treat Analysis, Laboratories, Maintenance Chemotherapy, Male, Oxadiazoles - adverse effects, Oxadiazoles - therapeutic use, Patients, Placebos, Remission, Remission (Medicine), Sphingosine 1 Phosphate Receptor Modulators - adverse effects, Sphingosine 1 Phosphate Receptor Modulators - therapeutic use, Sphingosine 1-phosphate, Tumor necrosis factor-TNF, Ulcerative colitis